Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 13, 2023 09:00 ET | Source: Editas Medicine, Inc.

Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9

Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY™ (exagamglogene autotemcel) Agreement extends Editas Medicine’s cash runway into 2026 CAMBRIDGE, Mass., Dec. 13,...
December 11, 2023 12:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar

All RUBY patients with ≥5 months follow-up have achieved a normal hemoglobin level and a fetal hemoglobin level of >40% All patients treated in the RUBY trial are free of vaso-occlusive...
November 03, 2023 07:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Third Quarter 2023 Results and Business Updates

Company to provide a clinical update on the EDIT-301 RUBY trial for SCD and EdiTHAL trial for TDT in December at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored...
November 02, 2023 09:12 ET | Source: Editas Medicine, Inc.

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar

Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ET Dr. Rabi Hanna from Cleveland Clinic Children’s to present EDIT-301 clinical data at ASH on Monday,...
October 27, 2023 07:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events

CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast...
October 16, 2023 08:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease

CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA)...
September 25, 2023 16:30 ET | Source: Editas Medicine, Inc.

Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s...
September 25, 2023 09:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company’s...
August 30, 2023 09:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Upcoming Investor Events

CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following...
August 02, 2023 07:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Second Quarter 2023 Results and Business Updates

On track to dose 20 total patients in the EDIT-301 RUBY trial for SCD and provide a clinical update by year-end Commenced parallel patient dosing in the EDIT-301 EDITHAL trial for TDT and on...